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The continuous emergence of drug-resistant viruses is a major
obstacle for the successful treatment of viral infections, thus
representing a persistent spur to the search for new therapeutic
strategies. Among them, multidrug treatments are currently at the
forefront of pharmaceutical, clinical, and computational investiga-
tion. Still, there are many unknowns in the way that different
drugs interact among themselves and with the pathogen that they
aim to control. Inspired by experimental studies with picornavirus,
here, we discuss the performance of sequential vs. combination
therapies involving two dissimilar drugs: the mutagen ribavirin
and an inhibitor of viral replication, guanidine. Because a system-
atic analysis of viral response to drug doses demands a precious
amount of time and resources, we present and analyze an in silico
model describing the dynamics of the viral population under the
action of the two drugs. The model predicts the response of the
viral population to any dose combination, the optimal therapy to
be used in each case, and the way to minimize the probability of
appearance of resistant mutants. In agreement with the theoret-
ical predictions, in vitro experiments with foot-and-mouth disease
virus conﬁrm that the suitability of simultaneous or sequential
administration depends on the drug doses. In addition, intrinsic
replicative characteristics of the virus (e.g., replication through
RNA only or a DNA intermediate) play a key role to determine the
appropriateness of a sequential or combination therapy. Knowl-
edge of several model parameters can be derived by means of
few, simple experiments, such that the model and its predictions
can be extended to other viral systems.
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The ability of diverse and rapidly multiplying parasites toadapt to environmental changes is a major obstacle for the
design of successful therapeutic strategies able to control their
proliferation and propagation. RNA viruses count among the
most plastic organisms on Earth and are an iconic example of
populations persistently escaping the action of antiviral drugs (1,
2). Drugs exert constant selection pressures on viral populations,
and as such, the question is not whether a resistant form of the
virus will appear but when it will occur. Alternative therapies are
continuously sought with the aim of impeding the appearance
and ﬁxation of resistance mutants (3–5). Among them, multi-
drug treatments have been established as an efﬁcient way of
delaying the appearance of resistant forms. However, to under-
stand the mode of action of combined treatments, it is urgent to
clarify the degree of interaction between the different drugs
used (6) and the quantitative impact that they have on the virus
that they are affecting. The joint action of two drugs can rarely
be reduced to the simple addition of their independent effects
(7), and the same drug might elicit different responses in dif-
ferent viral systems, including the appearance of compensatory
mutations able to induce resistance (8). Thus, the complete
characterization of a multidrug treatment applied to a particular
viral system might require in the last term a systematic assay with
a large number of drug doses delivered under different admin-
istration protocols. A full characterization of the response of the
viral system in vitro is needed before any in vivo assay of the
treatment. This procedure demands a costly amount of time and
resources that can be signiﬁcantly reduced through the guide
offered by formal approaches to therapies.
Knowledge derived from in vitro studies of the response of
pathogens to the action of one or a number of drugs might be
combined with the information yielded by well-designed math-
ematical models involving the relevant mechanisms of action of
and interaction among the drugs (9, 10), virus–host interactions
(11), or role of the immune response (12). An important feature,
rarely taken into account, is the intrinsic replicative ability of the
pathogen. Many different ways to encode genomic information
(ds- and ssRNA and different polarities) and a repertoire of
replicating strategies have been selected by different RNA
viruses. Hence, the knowledge gained for a particular virus may
not be extrapolated to other systems, although suitable mod-
iﬁcations of dynamical models can likely account for these dif-
ferent replication modes.
The dynamics of the picornavirus foot-and-mouth disease vi-
rus (FMDV) have been explored under different experimental
regimens with the aim of disclosing protocols able to cause its
extinction during replication in cell culture. It has been shown
that a combination of mutagenic agents and antiviral inhibitors
is an efﬁcient way to drive FMDV to extinction (13, 14). The
mutagen succeeds in raising the fraction of defective and lethal
mutants in the population, thus decreasing its overall ﬁtness.
Defectors may also interfere with infectivity, as shown with
speciﬁc mutants (15) and preextinction viral populations (16),
and thus, accelerate extinction. For its part, the inhibitor con-
tributes to extinction by reducing the viral load. However, the
joint effect of a mutagen and an inhibitor cannot be reduced to
the addition of their individual effects (9). Since the dawn of
quasispecies theory (17), the use of mutagens has been proposed
as a plausible strategy to induce viral extinction (18, 19). A sig-
niﬁcant increase in the mutation rate has been, indeed, suc-
cessful to cause the extinction of infectivity in many different
viral systems (20, 21), although the mechanisms through which
extinction supervenes are diverse and related to a variety of
molecular and population responses (22). In particular, in-
creased mutagenesis can also bear beneﬁcial effects for viral
populations through an enhancement of their diversity, which
promotes adaptation of low-ﬁtness viruses (23) and facilitates the
appearance of resistance mutants when an inhibitor of viral
replication is present (24).
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The increased likelihood of developing resistance to the in-
hibitor when dispensed simultaneously with a mutagen is what
advocates the sequential administration of the two drugs, with the
inhibitor followed by the mutagen. In a study with FMDV sub-
jected to the action of the mutagen ribavirin (R) and the inhibitor
of viral replication guanidinium hydrochloride (GU), it was
shown that, under the experimental conditions assayed, the se-
quential therapy performs better than the simultaneous admin-
istration of both drugs (24). This ﬁnding is an interesting result
that immediately queries the range of applicability and relative
success of combined or sequential administration of those two
dissimilar drugs. In this contribution, we face the characterization
of the response of a general viral system to the action of an in-
hibitor of its replication and a mutagenic agent through a model
for the dynamics of two different viral classes in the viral pop-
ulation. We obtain several exact results that predict the preferred
therapy as a function of intrinsic viral characteristics and the
administered drug doses. Our predictions are tested and con-
ﬁrmed by experiments with FMDV at different doses of inhibitor.
Results
Mathematical Model. The present model is intended to reproduce
the dynamics of a viral population after the addition of mutagens
and/or replication inhibitors using the protocol represented in
Fig. 1. Mutagens mostly promote the appearance of deleterious
variants, although some particular mutations may, however,
confer resistance to the inhibitor, thus favoring its survival. To
capture this double role of the mutagen, the model considers
that the dynamics are dominated by two types of individuals:
viable individuals that are susceptible to the inhibitor (v) and
viable individuals that are resistant to the inhibitor (V). Viable
individuals are able to infect cells and replicate by themselves.
Let w0 be the rate at which viable individuals produce, under
replication, a nonviable class, including lethal variants, defective
interfering forms, or any other mutant unable to complete an
infection cycle on its own [(1 − w0) is the intrinsic copying ﬁdelity
of the virus].† Resistant forms appear at a rate of μ0 = kw0.
Because mutations providing resistance to the inhibitor are rare
compared with deleterious ones, k ≪ 1.‡ Addition of a mutagen
is implemented by increasing the mutation rate from its natural
value w0 to a higher w > w0. As a consequence, the rate of ap-
pearance of resistant mutants, μ = kw, increases when the mu-
tagen is added. Each time a viral genome replicates inside the
cell, m copies are produced, and therefore, m is the replicative
ability per genome and replication cycle. The effect of an in-
hibitor is to slow down replication of the susceptible type by
multiplying parameter m by a factor 0 < i ≤ 1.
Let v(g) and V(g) denote the number of individuals of each type
at replication cycle g. Populations after one replication cycle in the
presence of a mutagen and an inhibitor will be (Eqs. 1 and 2)
vð g þ 1Þ ¼ ið1− μ−wÞmvð gÞ and [1]
V ð g þ 1Þ ¼ iμmvð gÞ þ ð1−wÞmV ð gÞ: [2]
To study the dynamics of the model and compare the sequential
vs. the combined administration of the drugs, we will mimic the
protocol described in Fig. 1. At cycle 0 (initial condition), we will
assume that the population is formed by S0 individuals of type v,
which because of mutations, will populate the class or resistant
mutants in successive replication cycles. A full solution of the
model is given in Materials and Methods. The dynamics of the
combined therapy correspond to applying Eqs. 1 and 2 iteratively
for g = 1, . . . , G cycles with parameters i < 1 and w > w0; the
dynamics of the sequential therapy imply replication for G cycles
in absence of the mutagen (i < 1 and w = w0) and use of the
generated population as initial condition to replicate for G ad-
ditional cycles in absence of the inhibitor and presence of the
mutagen (i = 1, w > w0).
Model Analysis. Viral particles are released from the cell after G
replication cycles. This release ﬁnishes the process for the
combined therapy, whereas there is a second passage to undergo
in the sequential therapy. The size of the infective population [let
us call it YT(G, w, i) to make explicit the experimental parame-
ters involved] is obtained by adding the population of individuals
in the two relevant classes after the ﬁrst passage, YT(G, w, i) =
v(G) + V(G) (Materials and Methods), and therefore (Eq. 3),
YTðG;w; iÞ ¼ S0mG
0
B@iGð1− μ−wÞ
Gð1− iÞ þ iμð1−wÞG− 1
1− i
1− μ−w
1−w
1
CA;
[3]
which for i = 1 (absence of inhibition), yields YT(G, w, 1) =
S0m
G(1 − w)G. The size of a viable viral population after one
passage with a mutagen and/or a replication inhibitor is, thus,
given by Eq. 3 with the corresponding parameters w and i. In the
absence of drugs, the total population obtained is S0m
G(1 −
w0)
G, such that the initial population is simply multiplied by
m(1 − w0) at each replication cycle, which is the basic re-
productive ratio of the population.
Comparison between treatments: Viral titer. Let us call Y CT the viral
titer after the application for one passage of the combined
treatment. According to the experimental protocol, the mutagen
and the inhibitor have been simultaneously administered, and
A
B
C
Fig. 1. Schematic outline of the experimental protocol in cell culture. (A)
Combined therapy. A dose dGU of guanidine and a dose dR of ribavirin are
simultaneously added to the initial population. The viral titer YCT is calculated
after a single passage. (B) Sequential therapy. A dose dGU is added to the
initial population. After 24 h, the inhibitor is removed, and a dose dR of ri-
bavirin is added. The viral titer YST is obtained after this second passage. (C)
Experimental results in a case example. The initial population has a titer of
3.7 × 106 pfu/mL. The applied doses are dGU = 18 mM and dR = 5 mM. With
these drug doses, the viral titers after applying the protocols described in A
and B are YCT ¼ 2× 102 pfu/mL and YST ¼ 10 pfu/mL, respectively. Passages
are performed and quantiﬁed as described in Materials and Methods.
†Under low multiplicity of infection (MOI), only viable individuals can infect new cells.
Independent of the size of the population of nonviable mutants, they are unable to
produce infection in the next passage because of the low MOI (from 10−5 to 10−1 pfu/
cell) (Materials and Methods). This is the reason why the dynamic equations for non-
viable types are not explicitly considered.
‡For the sake of simplicity, back mutations are not considered in the model. They would
represent a small contribution to the population numbers of type v in the form of an
additive term of order mμ and do not signiﬁcantly affect population dynamics, because
initially, only susceptible individuals are present. Note that a term of the same order is,
however, required to trigger the growth of population V. After resistant individuals have
appeared, their dynamics are dominated by the term of order (1 −w)m, in front of which
the ﬁrst term could be then discarded.
Iranzo et al. PNAS | September 20, 2011 | vol. 108 | no. 38 | 16009
M
ED
IC
A
L
SC
IE
N
CE
S
therefore, the viral yield is immediately given by Eq. 3:
Y CT ¼ YTðG;w; iÞ. Analogously, YST is deﬁned as the viral yield
after the sequential administration of the drugs: ﬁrst, the in-
hibitor for one passage and then, the mutagen for a second
passage (Eq. 4),
YST ¼ S− 10 YTðG;w0; iÞYTðG;w; 1Þ; [4]
where the initial condition for the second passage requires S0 to
be substituted by the yield obtained, YT(G, w0, i). The compar-
ison of the yields obtained using either treatment determines
which of them is more efﬁcient for each dose of mutagen and
inhibitor. The curve CCS, deﬁned by Y CT ¼ Y ST , separates two
regions in the space of parameters {i, w}, where one therapy or
the other is better suited to obtain a low viral titer (Materials and
Methods has an approximate expression of curve CCS and its
asymptotic value at large values of the inhibitor). Fig. 2 A, C, and
E shows the viral titer corresponding to the numerical solution of
the equations above for the combined and sequential treatments.
Comparison between treatments: Appearance of resistant mutants. In
addition to the viral titer produced after application of one or
another therapy, it is important to know the fraction of resistant
mutants that each treatment produces on average. This quantity
corresponds to the ﬁnal populations of type V(G) after one
passage with both the mutagen and the inhibitor (combination
therapy) or one passage with the inhibitor plus a second pas-
sage with the mutagen (sequential therapy). Let us call RC and
RS the two ﬁnal populations of resistants. The exact expressions
for the two quantities are obtained as RC = V(G, w, i) and
RS ¼ S− 10 vðG;w0; iÞV ðG;w; 1Þ þmGð1−wÞGV ðG;w0; iÞ, analo-
gous to the way in which the titers were obtained. The amount of
resistants produced with either treatment will be equal at values
of w and i that fulﬁll RC = RS. This ﬁnding deﬁnes curve CR. A
convenient way of calculating some of the properties of that
curve is to express the difference in the number of resistants
generated for a pair of values {w, i} as ΔR(w, i) = ΔY(w, i) − ΔS
(w, i), where ΔRðw; iÞ ¼ RC −RS ;ΔY ðw; iÞ ¼ Y CT −YST ; ΔS(w, i) =
S0(im(1 − μ − w))G(1 − mG(1 − μ0 − w0)G) is deﬁned as the dif-
ference in the amount of susceptible virus produced by the com-
bined and sequential treatments, with v(G, w, i) as calculated in
Materials and Methods.
The values of ΔR(w, i), when the yields of the two treatments
are equal [that is, on curve CCS, where ΔY(w, i) = 0], are always
positive, because ΔS(w, i) < 0 because of the biological fact that
the replication rate of the susceptible type is larger than one in the
absence of drugs: m(1 − μ0 − w0) > 1 and 1 ≥ μ + w. The pro-
duction of resistant mutants is, thus, lower through the sequential
treatment when both therapies are equally efﬁcient in terms of
total titer. This ﬁnding also implies that curve CR is always above
curve CCS (Fig. 2F). Hence, there is a region of doses of mutagen
and inhibitor between curves CR and CCS where the combination
treatment leads to lower titers but at the same time, the sequential
treatment causes a lower population of resistants.
In the limit of high doses of the inhibitor, i → 0, and because
limi → 0Δv(w, i)→ 0 (the population of susceptibles is completely
suppressed), the total population coincides with the population
of resistants and ΔR(w, i)→ ΔY(w, i). As a result, the limit value
of w on curve CR coincides with the limit value of w on curve CCS
(Materials and Methods).
Effect of treatment and virus parameters. Not all possible drug doses
are experimentally meaningful. First, there is a minimum amount
of mutagen required for the therapy to be effective, and it cor-
responds to those values of w large enough to cause a decrease of
viral yield in the absence of the inhibitor. This condition takes
the formal expression m(1 − w) < 1. We, thus, deﬁne curve Cw as
those points where m(1 − w) = 1, separating the regions of in-
crease and decrease of the population size under the action of
the mutagen. A similar reasoning leads to curve Ci, which marks
the values of i below which the inhibitor is able to cause a
decrease of the viable population before resistance appears,
(im)G(1 − w0)G = 1.
There is a limit under high enough values of the drug dose
where either treatment may cause the extinction of the virus with
the applied protocol. Curve CCe is determined by those combi-
nations of {i, w} where the population size of the combined
treatment falls below one. The exact solution for curve CCe can
only be given in implicit form as those values solution of YT(G, w,
i) = 1. To ﬁrst order in μ, the curve fulﬁls the approximate ex-
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Fig. 2. Theoretical phase space representation of the model. (A) Viral titer
YCT after application of the combination treatment. (B) Doses that fall on the
gray area cause viral extinction under application of the combination
treatment. The frontier with the blue region corresponds to values {i, w}
yielding YCT ¼ 1, which deﬁnes curve CCe . (C) Viral titer YST after application of
the sequential treatment. (D) Doses that fall on the gray area cause viral
extinction under application of the sequential treatment. The frontier with
the red region corresponds to values {i, w} yielding YST ¼ 1, which deﬁnes
curve CSe . (E) Comparison of the titers produced by combination and se-
quential therapies. In the z axis, we represent the minimum value of the viral
yield for each pair of {i,w} values. (F) In the gray area, extinction occurs if the
appropriate therapy is used. Blue and red lines correspond to extinction with
the combination or sequential treatment, respectively, and are as above.
Black curve is CCS. It signals the pairs of {i, w} values where both therapies
produce the same titer. Violet curve CR indicates when both treatments
produce the same amount of resistants. In the violet region between CR and
CCS curves, the combined treatment yields the lower titer, but the sequential
treatment is less prone to produce resistance. In the limit of large amounts
of inhibitor (i → 0), both therapies perform equally well in regard to titer
and resistant production. The expression for the limit value of mutagenwi → 0
(Materials and Methods) is indicated with an arrow in the plot. Finally, the
dotted line stands for curve Ci, which indicates the values of i (below the curve)
that cause an efﬁcient decrease of the population. Curve Cw, representing the
values of the mutagen above which the population of viable individuals
decreases from passage to passage, is out of the range shown in the plots.
Parameters for all plots are m = 50, G = 2.5, w0 = 0.9, and k = 0.01.
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pression mGS0(1 − w)G − 1(iG(1 − w) + kwγ) ≅ 1. Analogously,
curve CSe is deﬁned by those pairs {i, w} at which S0
−1YT(G, w0, i)
YT(G, w, 1) = 1. Fig. 2 illustrates, in a representative case, the
response of a viral population to the action of a combined or
sequential treatment. All curves deﬁned above (except for Cw,
which occurs at values of w quite far from the domains shown)
are represented in Fig. 2 B, D, and F.
Parameters m and G depend signiﬁcantly on the mode of
replication of the virus inside an infected cell. ssRNA viruses are
characterized by large values of m and probably, quite low values
of G. In double-stranded genomes with semiconservative repli-
cation, one would expect a value of m ∼ 2 and a larger value of
G. In both cases, the accumulation of mutations proceeds dif-
ferently, and therefore, w0 would also vary accordingly. The
model presented here cannot be directly applied to viruses that
use other replication modes, such as retroviruses (with a DNA
provirus phase) or DNA viruses such as the herpesviruses that
include a latency step. Extension to such systems would require
signiﬁcant modiﬁcations of the dynamical rules.
Case of FMDV with R and GU. The determination of viral pro-
ductivity for a virus growing in excess of resources (P0) in the
presence of a given amount of mutagen (Pw) and inhibitor (Pi)
bounds for the values of the model parameters (SI Text). Because
FMDV is an ssRNA virus, we take m between 50 and 1,000. As
for the intrinsic mutation rate w0, data available put it in the
range of 0.4–0.9. With a basal productivity of P0 = 460 ± 35, G is
bounded between 1 and 3.8. Estimation of Pw yields the range of
possible values of w, which is bounded between 0.992 and 0.999.
Similarly, estimation of the productivity in the presence of dif-
ferent doses of the inhibitor permits estimating parameter i as i=
(Pi/P0)
1/G (SI Text). More accurate measurements of the viral
parameters by means of speciﬁc experiments directed to quantify
m, G, and/or w0 could signiﬁcantly narrow the intervals com-
patible with the experimental results.
Results with FMDV subjected to the therapeutic protocols
described under ﬁxed doses of R and GU revealed that the se-
quential treatment could be better suited to cause viral extinction
(24). However, in the light of the model described, the adequacy
of sequential vs. combination treatment with a mutagen and an
inhibitor of the viral replication depends on (i) the administered
doses and (ii) the natural productivity of the virus when infecting
a given host (i.e., parameters m, w0, and G). In particular, the
model predicts that, in most cases at a sufﬁciently low amount of
inhibitor and for a ﬁxed value of the amount of mutagen, the
combination treatment should yield a lower titer, the same
change holding for a ﬁxed amount of inhibitor and a sufﬁciently
low amount of mutagen. Increase of the doses dGU or dR above
a threshold value changes the treatment that produces the lower
amount of infectious virions. To test this prediction, we carried
out several experiments at increasing doses of inhibitor and
compared the viral yield after both therapeutic protocols (Fig.
3A). At low doses of inhibitor, the combined therapy causes
lower viral yields than the sequential therapy. However, for a
dose of the inhibitor between 6 and 12 mM, it is the sequential
treatment that begins to yield lower viral titers. The effect of the
therapies is, thus, exchanged as theoretically predicted (Fig. 3B).
Discussion
Ever since the quasispecies dynamics were revealed as general
for pathogenic RNA viruses and retroviruses, the problem of
treatment failure because of selection of drug-escape viral
mutants was recognized (25). Several approaches have been used
in medical practice to minimize selection of viral mutants re-
sistant to antiviral agents. The most successful strategy was the
implementation of combination therapy involving the simulta-
neous administration of two or more drugs directed to different
viral targets. The advantages of combination therapy over
monotherapy stem from basic statistical considerations on the
frequency of generation of multidrug-resistant mutants (25). The
advantage of combination vs. various regimens of sequential or
treatment interruption (structured treatment interruptions or
drug holidays) regimens has been supported by results of mul-
tiple clinical trials as well as theoretical models of viral dynamics
(5, 11, 26–30). However, whenever residual viral replication is
allowed, viral rebound and treatment failure often occur. For
this reason, new proposals for the administration of drugs have
been made. A recent one, yet to be tested in clinical trials, is the
so-called proactive treatment in two steps: an induction regimen
aimed at reducing the background of viral mutants followed by
a maintenance regimen to control the viral load for extensive
time periods (31). An alternative strategy is to target cellular
factors needed for viral replication either alone or combined
with drugs directed to viral functions (32). Provided no toxic
effects on the cells intervene, resistance to inhibitors of cellular
functions can also develop when the host factor interacts with
viral nucleic acids or proteins.
Lethal mutagenesis introduces an important element in anti-
viral therapy in that a mutagenic agent is involved in treatment.
When administered together with a nonmutagenic inhibitor, the
mutagen can play a dual and opposite role: to deteriorate viral
A
B
Fig. 3. Experimental protocol results using FMDV infection of cell cultures.
Comparison with theoretical predictions. (A) Experimental results. Passages
were carried out by infecting 2 × 106 BHK-21 cells with pMT28 strain of
FMDV (0.2 mL supernatant from the previous passage), and infectivity levels
were determined as detailed in Materials and Methods. The combination or
sequential protocol therapies were applied in the presence of a dose of
mutagen dR = 5 mM and increasingly high doses of viral inhibitor, dGU = 3, 6,
12, or 20 mM, as indicated. The combination treatment is indicated in
brackets (Left), whereas for the sequential treatment, the order of admin-
istration of GU and R is separated by a comma (Right). A control measure is
shown for reference (ﬁrst left bar in each panel), and other columns rep-
resent the mean ± SD (error bars) from triplicate determinations. The dis-
continuous lines in the virus titers indicate the limit of detection of
infectivity. (B) Comparison of experimental results with the predictions of
the model. Viral titers expected after applying the sequential or combina-
tion protocol in the mathematical model are shown as continuous lines
(blue, combined treatment; red, sequential treatment; color code for data is
the same as in A). Curves obtained with parameters that yield the least
squares deviation to the logarithm of experimental data are shown as blue
(combination) and red (sequential) curves. The obtained parameters arew0 =
0.76, w = 0.998, k = 0.005, and m = 195. The values of the inhibitor i = 4.25 ×
10−2, 3.47 × 10−3, 2.10 × 10−4, and 1.41 × 10−4, corresponding to the four
doses assayed, are shown in the x axis (SI Text).
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functions because of the excess mutations that it provokes, and
increase the frequency of mutations that confer resistance to the
partner, coadministered inhibitor. An advantage of a sequential
over combination treatment during lethal mutagenesis protocols
was suggested by a study of lethal mutagenesis of FMDV (33),
and this advantage prompted the theoretical generalization
reported in the present study and has been further supported by
additional experiments also reported herein.
In this contribution, we have developed a theory that quanti-
tatively describes the response of a viral population under two
different protocols that involve the action of an inhibitor of viral
replication and a mutagenic drug. A limited number of simple
experiments allows us to estimate the parameters that describe
the dominant processes, and knowledge of these few relevant
parameters permits us to predict the behavior of the model for
other combinations of drugs. Two important outcomes of the
treatments have to be considered when choosing between a com-
bined or sequential administration of the drugs: in a region of
mutagen and inhibitor doses that can be calculated, the viral titer
produced by one or another therapy is minimized. Furthermore,
there is a domain of drug doses where combination treatment
yields the lower titer, but the probability of appearance of mutants
resistant to the inhibitor is lower with a sequential treatment. The
use of analogous models can signiﬁcantly reduce the number of
in vitro assays to be performed in other viral systems as well, where
different replication strategies should translate into dynamical
equations similar to our Eqs. 1 and 2. The simulation of an in vivo
situation entails additional difﬁculties, like development of a large
viral population from an infecting seed, interaction with the im-
mune system, or environmental and individual characteristics that
may not lead to deterministic equations but should be included as
noisy, ﬂuctuating dynamical variables. The predictions of the
model after being tested in vitro could be taken only as a rough
guide to apply one or another administration protocol and infer
minimum drug doses in in vivo assays.
Our predictions acquire more relevance in view of the evi-
dence that lethal mutagenesis can indeed be effective in vivo (34)
and that some clinical trials for AIDS patients that involve ad-
ministration of a mutagenic nucleoside analog have been im-
plemented (35). Our results will be particularly relevant when
considering a lethal mutagenesis approach to combat viruses for
which a repertoire of nonmutagenic inhibitory agents is already
available. Detailed predictions of the viral response tailored to
the particular system under study are now possible.
Materials and Methods
Cells and Viruses. The origin of BHK-21 cells and procedures for cell growth in
DMEM and plaque assays in semisolid agar have been previously described
(36, 37). FMDV C-S8c1 is a plaque-puriﬁed derivative of serotype C isolate C1
Santa Pau-Sp70 (37). An infectious clone of FMDV C-S8c1, termed pMT28,
was constructed by recombining into pGEM-1 plasmid subclones that rep-
resented the C-S8c1 genome as described (38, 39). Thus, FMDV pMT28 used
in the experiments is the progeny of infectious transcripts that express the
standard FMDV C-S8c1. To control for the absence of contamination, mock-
infected cells were cultured, and their supernatants were titrated in parallel
with the infected cultures; no signs of infectivity or cytopathology in the
cultures or control plaque assays were observed in any of the experiments.
Treatment with R and GU. A solution of GU in DMEM was prepared at
a concentration of 50 mM, sterilized by ﬁltration, and stored at 4 °C. A so-
lution of R in PBS was prepared at a concentration of 100 mM, sterilized by
ﬁltration, and stored at −70 °C. Before use, the stock solutions were diluted
in DMEM to reach the desired concentration. For infections of BHK-21 cells
with FMDV in the presence of GU, no pretreatment of the cell monolayer
with GU was performed. For infections in the presence of R, cell monolayers
were pretreated during 7 h with 5 mM R before infection. After addition of
FMDV and washing of the cell monolayers, infections were allowed to
continue in the presence of a combination of GU + R or sequential passages
consisting of a ﬁrst passage in the presence of GU and a second passage in
the presence of R. For the combination treatment, the infections were car-
ried out at an MOI of 0.4 pfu/cell. For the sequential treatment, the initial
infection in the presence of increasing concentrations of GU was carried out
also at an MOI of 0.4 pfu/cell. The second infection in the presence of 5 mM
R was carried out at MOIs of 1.1, 2.0 × 10−2, 2.2 × 10−4, and 1.2 × 10−4 pfu/cell
for GU 3, 6, 12, and 20 mM GU, respectively. Infections in the absence of GU,
R, or a combination of GU + R and mock-infected cells were maintained in
parallel, and no evidence of contamination of cells with virus was observed
at any time.
Complete Solution of Eqs. 1 and 2. The dynamics of the model system can be
written in compact form through the vector n(g), whose components are the
number of individuals in each of the classes v and V after g replication cycles
(Eq. 5):
nðgþ 1Þ ¼ mAnðgÞ; [5]
with A being the transition matrix of the system (Eq. 6),
A ¼

iβ 0
iðα− βÞ α

; [6]
and where we have deﬁned α = 1 − w and β = 1 − μ − w. This dynamical
system can be exactly solved for the initial condition n(0) = {S0, 0} to yield the
population of each viral class after g cycles (Eqs. 7 and 8),
vðgÞ ¼ S0ðimÞgβg and [7]
VðgÞ ¼ S0img

α− β
α− iβ

αg − ðiβÞg; [8]
from where the exact expression for the total number of viable elements is
obtained (Eq. 3).
Approximate Analytic Expression for CCS. The expression obtained from Eq. 4
yields the dependence between w and i in an essential nonalgebraic way,
and therefore, it can be only numerically solved. However, if we assume that
μ ≪ 1, an expansion in powers of μ yields the following approximate de-
pendence for the points on curve CCS (Eq. 9):
wc ¼ 1− kγ
kγ − iG þmGð1−w0ÞG

iG þ γμ0=ð1−w0Þ
 ; [9]
where γ = [i + iG(iG − i − G)]/(1 − i). Given the amount of mutagen i, the
sequential treatment causes a larger decrease in the viral titer for values of
w > wc, whereas the combined treatment is more efﬁcient for w < wc. The
preferred therapy changes as well if the value of w is ﬁxed and the amount
of inhibitor increases. For values of i close to one, the combined treatment is
better, whereas the sequential treatment will be preferred above a certain
amount of inhibitor. Curve (Eq. 9) has two important limits, absence of in-
hibitor (i → 1) and large doses of inhibitor (i → 0). In the former case, both
treatments become equivalent for values of w → 1 (Fig. 2F), a situation
where all genomes produced under replication would be nonviable. Actu-
ally, w = 1 cannot be empirically tested, because the complete extinction of
the population occurs at values of w below one, which will be shown.
However, there is a saturation effect when the amount of inhibitor is very
high in the sense that additional decreases in i diminish the viral titer but do
not change the preference for one or another therapy (Eq. 10):
wi→0 ≡ lim
i→0
wc ¼ m
Gw0ð1−w0ÞG− 1
mGw0ð1−w0ÞG−1þ1
; [10]
which is independent of i.
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